Kyverna has experienced leadership from Kite Therapeutics veterans with proven CAR-T market expertise. The company maintains ample funding with cash runway extending well into 2027 without additional fundraising. The company has a license and collaboration agreement with Intellia Therapeutics to develop an allogeneic CD19 CAR T-cell product.
Cyborg Score Rationale
KYV-101 achieved all primary and secondary endpoints in Phase 2 gMG trials with 100% of patients achieving rapid, robust reductions in disease markers by week 24. The company expects topline SPS data in early 2026 with BLA submission anticipated in the first half of 2026, potentially bringing the first CAR-T therapy to market for autoimmune disease.
Top Insights
Positive interim Phase 2 data in gMG demonstrated all primary and secondary endpoints with 100% of patients achieving rapid, robust disease reduction sustained through 24 weeks, positioning KYV-101 as potentially transformative therapy.
Landmark Phase 2 results in stiff person syndrome could enable miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease with BLA submission planned for 1H 2026.
The company secured up to $150M loan facility in November 2025 to support late-stage development and pre-launch activities for gMG and SPS indications.
Kyverna's pipeline targets multiple high-value B cell-driven autoimmune diseases including MS, myasthenia gravis, stiff-person syndrome, and lupus nephritis across rheumatology and neurology.
Named Competitors
CAR-T Cell Therapy — Developing CAR-T therapies for autoimmune diseases